{"denoms":[{"counts":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"417"}],"units":"Participants"}],"groups":[{"description":"Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle.","id":"BG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.2","value":"61.5"},{"groupId":"BG001","spread":"11.7","value":"62.0"},{"groupId":"BG002","spread":"11.4","value":"61.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"161"}],"title":"< 60 years"},{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"256"}],"title":">= 60 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"218"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"199"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"249"}],"title":"Europe"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"72"}],"title":"North America"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"96"}],"title":"Asia"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Missing"},{"measurements":[{"groupId":"BG000","value":"130"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"259"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"143"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}],"title":"2"}]}],"description":"The ECOG PS required for the study was 0 (fully active), 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), or 2 (ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours)","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG (Eastern Cooperative Oncology Group) performance status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"359"}]}],"title":"Lung"},{"categories":[{"measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"214"}]}],"title":"Lymph node"},{"categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"113"}]}],"title":"Bone"}],"description":"Participants could have had more than one site.","paramType":"NUMBER","title":"Site of target/nontarget lesions at baseline - organ class","unitOfMeasure":"Participants"}]}